Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Accounts Payables (2016 - 2023)

Endonovo Therapeutics has reported Accounts Payables over the past 13 years, most recently at $1.2 million for Q3 2023.

  • Quarterly results put Accounts Payables at $1.2 million for Q3 2023, up 36.41% from a year ago — trailing twelve months through Sep 2023 was $1.2 million (up 36.41% YoY), and the annual figure for FY2022 was $884195.0, up 34.28%.
  • Accounts Payables for Q3 2023 was $1.2 million at Endonovo Therapeutics, up from $1.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for ENDV hit a ceiling of $1.2 million in Q3 2023 and a floor of $198885.0 in Q1 2019.
  • Median Accounts Payables over the past 5 years was $711235.0 (2021), compared with a mean of $704554.1.
  • Peak annual rise in Accounts Payables hit 280.89% in 2019, while the deepest fall reached 93.35% in 2019.
  • Endonovo Therapeutics' Accounts Payables stood at $599470.0 in 2019, then increased by 16.93% to $700932.0 in 2020, then dropped by 6.06% to $658463.0 in 2021, then soared by 34.28% to $884195.0 in 2022, then surged by 33.56% to $1.2 million in 2023.
  • The last three reported values for Accounts Payables were $1.2 million (Q3 2023), $1.2 million (Q2 2023), and $879205.0 (Q1 2023) per Business Quant data.